Literature DB >> 12964418

Phenotypic analysis of plasma cells in bone marrow using flow cytometry in AL amyloidosis.

Masayuki Matsuda1, Takahisa Gono, Yasuhiro Shimojima, Yoshinobu Hoshii, Shu-ichi Ikeda.   

Abstract

AL amyloidosis is an intractable disease resulting from a plasma cell dyscrasia which has a wide clinical spectrum. To investigate the phenotype of plasma cells in the bone marrow, a flow cytometric analysis was carried out in 10 patients with this disease (mean age, 57.8 +/- 7.9 years) and controls with M-protein (positive controls, n = 4) and without it (negative controls, n = 8). All patients were shown to have either A kappa- or A lambda-immunoreactive amyloid deposits on the biopsied tissues. On flow cytometry CD38++CD19+CD56- cells (polyclonal plasma cells) showed no significant difference between patients (0.59 +/- 0.37%) and either negative (2.25 +/- 2.84%) or positive controls (0.38 +/- 0.20%), while CD38++CD19-CD56+ cells (monoclonal plasma cells) showed a significantly higher level in the patients (1.34 +/- 1.54%) than in either negative (0.041 +/- 0.004%, p < 0.005) or positive controls (0.11 +/- 0.09%, p < 0.05). With respect to maturation of plasma cells, five of the patients (50%), three of the positive controls (75%) and all of the negative controls showed a dominant proliferation of mature subtype (CD45+MPC-1+CD49e- or CD45+MPC-1+CD49e+). Immature (CD45+MPC-1- or CD45-MPC-1-) and intermediate (CD45-MPC-1+CD49e-) subtypes were dominantly present in the bone marrow in 2 and 3 patients, respectively. In AL amyloidosis monoclonal plasma cells producing M-protein can be easily and reliably detected in the bone marrow by flow cytometry. This analysis might provide plasma cell phenotypic markers useful for assessing the prognosis and for monitoring the response to treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12964418     DOI: 10.3109/13506120309041732

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  5 in total

Review 1.  Immunophenotyping in multiple myeloma and related plasma cell disorders.

Authors:  Shaji Kumar; Teresa Kimlinger; William Morice
Journal:  Best Pract Res Clin Haematol       Date:  2010-09       Impact factor: 3.020

2.  Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.

Authors:  Giovanni Palladini; Efstathios Kastritis; Mathew S Maurer; Jeffrey Zonder; Monique C Minnema; Ashutosh D Wechalekar; Arnaud Jaccard; Hans C Lee; Naresh Bumma; Jonathan L Kaufman; Eva Medvedova; Tibor Kovacsovics; Michael Rosenzweig; Vaishali Sanchorawala; Xiang Qin; Sandra Y Vasey; Brendan M Weiss; Jessica Vermeulen; Giampaolo Merlini; Raymond L Comenzo
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

3.  Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study.

Authors:  Vaishali Sanchorawala; Shayna Sarosiek; Amanda Schulman; Meredith Mistark; Mary Ellen Migre; Ramon Cruz; J Mark Sloan; Dina Brauneis; Anthony C Shelton
Journal:  Blood       Date:  2020-04-30       Impact factor: 22.113

4.  Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis.

Authors:  Katharina Lisenko; Stefan O Schönland; Anna Jauch; Mindaugas Andrulis; Christoph Röcken; Anthony D Ho; Hartmut Goldschmidt; Ute Hegenbart; Michael Hundemer
Journal:  Cancer Med       Date:  2016-04-25       Impact factor: 4.452

Review 5.  CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond.

Authors:  Dario Roccatello; Roberta Fenoglio; Savino Sciascia; Carla Naretto; Daniela Rossi; Michela Ferro; Antonella Barreca; Fabio Malavasi; Simone Baldovino
Journal:  Int J Mol Sci       Date:  2020-06-10       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.